• AcelRx Pharmaceuticals Inc., of Redwood City, Calif., received two notices of allowance for patent applications, titled "Small-Volume Oral Transmucosal Dosage Forms" and "Bioadhesive Drug Formulations for Oral Transmucosal Delivery." The patents describe a method of treating pain by adhering a small-volume solid tablet containing sufentanil to the oral mucosa, as well as compositions and dosage forms broadly covering NanoTab formulations.

• Advanced Cancer Therapeutics Inc., of Louisville, Ky., was granted U.S. Patent No. 8,088,385 B2, titled "PFKFB3 inhibitor for the treatment of a Proliferative Cancer."

• Allon Therapeutics Inc., of Vancouver, British Columbia, was granted a patent covering the use of its neuroprotective technology platform in the treatment of peripheral neuropathy, including lead drug candidate davunetide and pipeline product AL-309.

• Amarin Corp. plc, of Dublin, Ireland, received a notice of allowance for a patent application, titled "Highly Purified Ethyl EPA and Other EPA Derivatives," also known as the EPA with no DHA in a capsule application.

• Ampio Pharmaceuticals Inc., of Greenwood Village, Colo., received a notice of allowance for an additional patent for lead drug Ampion, covering compositions that include the use of the low-molecular-weight fraction of commercially available human serum albumin for any use.

• Ariad Pharmaceuticals Inc., of Cambridge, Mass., received U.S. Patent No. 8,114,874, titled "Substituted Acetylenic Imidazo[1,2-B] Pyridazine Compounds as Kinase Inhibitors." It provides composition-of-matter protection for investigational pan-Bcr-Abl inhibitor ponatinib.

• Arrowhead Research Corp., of Pasadena, Calif., received U.S. Patent No. 8,114,983, titled "Compositions and use of EPAS1 inhibitors," covering claims directed to siRNA sequences targeting the hypoxia-inducible factor 2 alpha gene or endothelial PAS domain protein 1, chemical modifications, compositions, methods and uses.

• Athersys Inc., of Cleveland, received U.S. Patent No. 8,147,824, which covers the use of nonembryonic, multipotent stem cells for the reduction in severity or prevention of graft-vs.-host disease.

• BioLineRx Ltd., of Jerusalem, received a notice of allowance covering the composition of BL-1040 for the prevention of cardiac remodeling following an acute myocardial infarction.

• Cortex Pharmaceuticals Inc., of Irvine, Calif., received two patents protecting the next generation of Ampakine compounds. Specifically, the patents cover a series of compounds, including preclinical compounds CX2007 and CX2076.

• Cytochroma Ltd., of Markham, Ontario, received a notice of allowance for a patent application, titled "Method for Treating Secondary Hyperparathyroidism in CKD," covering the anticipated method of use for lead product CTAP101 , in Phase III testing in Stage III and Stage IV chronic kidney disease patients.

• Galena Biopharma Inc., of Lake Oswego, Ore., received a notice of allowance for a patent covering the use of NeuVax, an HER2/neu peptide vaccine, for inducting immunity to breast cancer recurrence in patients having low to intermediate IHC ratings of 1+ or 2+ and a FISH rating of less than about 2.0.

• iBio Inc., of Newark, Del., received U.S. Patent No. 8,124,103, titled "Influenza Antigen, Vaccine Compositions and Related Methods." It covers the use of the firm's fusion-protein technology in combination with influenza virus antigens for vaccine product applications. The firm also received U.S. Patent No. 8,148,608, titled "Systems and methods for clonal expression in plants," covering compositions and methods for generating clonal cell lines and plants for expressing gene products.

• Indel Therapeutics Inc., of Vancouver, British Columbia, received a patent, titled "The Diagnosis and Treatment of Infectious Diseases through Indel-differentiated Proteins," covering claims for indel-based targeting in antimicrobial drug discovery.

• Inovio Pharmaceuticals Inc., of Blue Bell, Pa., received U.S. Patent No. 8,133,723, which covers the SynCon universal vaccine related to H1N1 influenza. Claims include the synthetic consensus H1 antigen and DNA constructs and vaccines, which include that antigen, including INO-3510.

• Intellect Neurosciences Inc., of New York, received a notice of allowance for patent claims covering the company's Antisenilin monoclonal antibody platform technology for the treatment and prevention of Alzheimer's disease.